Michele Trucksis, PhD, MD; David C. Hooper, MD; John S. Wolfson, MD, PhD
The fluoroquinolones are orally administered antimicrobial agents introduced in the mid-1980s. Although they are particularly effective for treating gram-negative bacillary infections, some agents, including ciprofloxacin, ofloxacin, and pefloxacin, are also active against gram-positive organisms. These agents have shown promise as alternatives to parenteral vancomycin for treating infections with methicillin-resistant Staphylococcus aureus. With fluoroquinolone use, however, therapeutic failures associated with isolation of fluoroquinolone-resistant strains of staphylococci are being increasingly documented. We discuss the use of fluoroquinolones as therapeutic agents for staphylococcal infections, problems with bacterial resistance, and approaches to suppression of resistance.
Staphylococci have long been important causes of both community-
Trucksis M, Hooper DC, Wolfson JS. Emerging Resistance to Fluoroquinolones in Staphylococci: An Alert. Ann Intern Med. ;114:424–426. doi: 10.7326/0003-4819-114-5-424
Download citation file:
Published: Ann Intern Med. 1991;114(5):424-426.
Results provided by:
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use